Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

NCT03751709 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Acute Lymphoblastic Leukaemia
ALL, Adult
B-ALL

Interventions

DRUG: Blinatumomab
OTHER: Haplo-Mismatched Cell Therapy (HMCT)

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]